Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
dc.contributor.author | Califano, Raffaele | |
dc.contributor.author | Griffiths, Richard W | |
dc.contributor.author | Lorigan, Paul C | |
dc.contributor.author | Ashcroft, Linda | |
dc.contributor.author | Taylor, Paul | |
dc.contributor.author | Burt, Paul A | |
dc.contributor.author | Lee, Lip W | |
dc.contributor.author | Chittalia, Abbas | |
dc.contributor.author | Harris, Maggie A | |
dc.contributor.author | Faivre-Finn, Corinne | |
dc.contributor.author | Thatcher, Nick | |
dc.contributor.author | Blackhall, Fiona H | |
dc.date.accessioned | 2012-05-28T11:39:26Z | |
dc.date.available | 2012-05-28T11:39:26Z | |
dc.date.issued | 2011-09 | |
dc.identifier.citation | Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. 2011, 73 (3):338-44 Lung Cancer | en_GB |
dc.identifier.issn | 1872-8332 | |
dc.identifier.pmid | 21296449 | |
dc.identifier.doi | 10.1016/j.lungcan.2011.01.001 | |
dc.identifier.uri | http://hdl.handle.net/10541/226211 | |
dc.description.abstract | The role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Lung cancer (Amsterdam, Netherlands) | en_GB |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Antineoplastic Protocols | |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung | |
dc.subject.mesh | Disease Progression | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Lung Neoplasms | |
dc.subject.mesh | Male | |
dc.subject.mesh | Maximum Tolerated Dose | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Neutropenia | |
dc.subject.mesh | Quality of Life | |
dc.subject.mesh | Survival Analysis | |
dc.subject.mesh | Taxoids | |
dc.subject.mesh | Thrombocytopenia | |
dc.subject.mesh | Treatment Outcome | |
dc.title | Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. | en |
dc.type | Article | en |
dc.contributor.department | Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. raffaele.califano@christie.nhs.uk | en_GB |
dc.identifier.journal | Lung Cancer | en_GB |
html.description.abstract | The role of chemotherapy for advanced NSCLC patients and ECOG PS2 remains controversial. We evaluated 4 doses of 3-weekly docetaxel to identify a less toxic, clinically effective dose. |
Files in this item
This item appears in the following Collection(s)
-
All Christie Publications
-
Medical Oncology
Medical Oncology -
Clinical Oncology
Clinical Oncology